- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | BIO-WORKS TECHNOLOGIES AB: Today is the first day of the sixth exercise period for Bio-Works Technologies AB's warrants of series TO 2 | 3 | Cision News | ||
| Mi | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB - Business Update first quarter 2026 | 1 | Cision News | ||
| 06.03. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB publishes Business Update ahead of next value creation phase | 1 | Cision News | ||
| 20.02. | BIO-WORKS TECHNOLOGIES AB: Bio-Works publishes Year-end report Q4 2025 | 5 | Cision News | ||
| BIO-WORKS TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 17.02. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Order from Returning Customer | 1 | Cision News | ||
| 19.01. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 5 of 11 | 5 | Cision News | ||
| 02.01. | BIO-WORKS TECHNOLOGIES AB: Business Update | 1 | Cision News | ||
| 29.12.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Two WorkBeads 100S and 100Q Orders Worth SEK 4 Million | 5 | Cision News | ||
| 15.12.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB Annual General Meeting to be held on Thursday 4 of June 2026 | 2 | Cision News | ||
| 07.11.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works reports third quarter 2025 | 1 | Cision News | ||
| 06.11.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives order for WorkBeads 40S from contract manufacturer in Europe | 3 | Cision News | ||
| 29.10.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works forms strategic partnership with Zenmindes Biotechnology to strengthen presence in China | 1 | Cision News | ||
| 21.10.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works two largest shareholders, members of the board and the CEO have all exercised all their Warrants TO2 | 1 | Cision News | ||
| 17.10.25 | BIO-WORKS TECHNOLOGIES AB: Correction: Bio-Works receives order for WorkBeads affimAb valued at approximately SEK 8.3 million | 4 | Cision News | ||
| 17.10.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives order for WorkBeads affimAb valued at approximately SEK 8.3 million | 1 | Cision News | ||
| 16.10.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 4 of 11 | 1 | Cision News | ||
| 08.10.25 | BIO-WORKS TECHNOLOGIES AB: Strong interest in WorkBeads affimAb Edge: Next-Generation Protein A Resin for Antibody Purification | 3 | Cision News | ||
| 07.10.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies wins appeal against the Swedish Tax Agency in the Supreme Administrative Court | 2 | Cision News |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HELIX BIOPHARMA | 0,820 | -7,87 % | Helix Biopharma GAAP EPS of -$0.05 | ||
| DAMORA THERAPEUTICS | 25,500 | +2,41 % | Damora Therapeutics, Inc.: Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 35,310 | +1,17 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| BIONTECH | 77,70 | +0,58 % | BioNTech überrascht: Krebsdaten geben Hoffnung! | BioNTech treibt den strategischen Wandel hin zu einem Onkologie-Unternehmen voran und erzielt dabei erste vielversprechende klinische Fortschritte, insbesondere im Bereich Lungenkrebs. Gleichzeitig... ► Artikel lesen | |
| EVOTEC | 4,503 | +1,03 % | Evotec Aktie nach Kurssturz: Chancen auf kurzfristige Wende | Findet die Evotec Aktie an der 4-Euro-Marke einen neuen Boden? Nachdem der monatelange Versuch einer Bodenbildung zwischen 4,90 Euro und 5,06/5,11 Euro jüngst endgültig scheiterte, hat sich die Biotech-Aktie... ► Artikel lesen | |
| ARCELLX | 114,75 | +0,00 % | Gilead extends Arcellx tender offer deadline to April 24 | ||
| ERASCA | 17,490 | +5,33 % | Erasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results | Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 52,99 | +5,57 % | What's Going On With Structure Therapeutics Stock On Wednesday? | ||
| TYRA BIOSCIENCES | 39,885 | +4,08 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 19,680 | +4,10 % | Summit Therapeutics (SMMT) Climbs 15.4% Ahead of Pipeline Q2 Updates | ||
| BEAM THERAPEUTICS | 24,440 | +0,97 % | Beam Therapeutics publishes sickle cell therapy trial data | ||
| ADMA BIOLOGICS | 9,020 | -0,99 % | ADMA Biologics, Inc.: ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research | Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and... ► Artikel lesen | |
| RELAY THERAPEUTICS | 12,980 | +20,52 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 | 400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Ka-mutated, HR+/HER2- metastatic breast... ► Artikel lesen | |
| VALNEVA | 2,704 | -3,70 % | Valneva: Wahrscheinlichkeit für Zulassung sinkt | Ein von Valneva und Pfizer entwickelter Lyme-Borreliose-Impfstoffkandidat (LB6V) hat in einer Phase-III-Studie den primären statistischen Endpunkt nicht erreicht. Die Aktie hat mit einem deutlichen... ► Artikel lesen | |
| TANGO THERAPEUTICS | 21,530 | +1,46 % | Tango Therapeutics is the best performing healthcare stock in March |
BIO-WORKS TECHNOLOGIES AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -3,46 % bei einem Aktienkurs von 0,307 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIO-WORKS TECHNOLOGIES AB finden Sie auf Wallstreet Online.